<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmateca</journal-id><journal-title-group><journal-title xml:lang="en">Pharmateca</journal-title><trans-title-group xml:lang="ru"><trans-title>Фарматека</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2073-4034</issn><issn publication-format="electronic">2414-9128</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">278639</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">INSULIN TREATMENT OF TYPE 2 DIABETES MELLITUS: A CHOICE AND AN INDIVIDUAL APPROACH</article-title><trans-title-group xml:lang="ru"><trans-title>ИНСУЛИНОТЕРАПИЯ САХАРНОГО ДИАБЕТА ТИПА 2: ВОЗМОЖНОСТИ ВЫБОРА И ИНДИВИДУАЛЬНЫЙ ПОДХОД</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Biryukova</surname><given-names>Ye V</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Biryukova</surname><given-names>Elena Valer'evna</given-names></name><name xml:lang="ru"><surname>Бирюкова</surname><given-names>Елена Валерьевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>Московский государственный медико-стоматологический университет, Москва</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff id="aff1"><institution></institution></aff><aff-alternatives id="aff2"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Московский государственный медико-стоматологический университет, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2010-08-20" publication-format="electronic"><day>20</day><month>08</month><year>2010</year></pub-date><volume>17</volume><issue>16</issue><issue-title xml:lang="en">NO16 (2010)</issue-title><issue-title xml:lang="ru">№16 (2010)</issue-title><fpage>46</fpage><lpage>52</lpage><history><date date-type="received" iso-8601-date="2023-02-23"><day>23</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2010, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2010, ООО «Бионика Медиа»</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2073-4034/article/view/278639">https://journals.eco-vector.com/2073-4034/article/view/278639</self-uri><abstract xml:lang="en"><p>Type 2 diabetes mellitus (DM2) is characterized by dangerous chronic complications, which lead to disability and reduction in the quality of life. Prevention of vascular complications of diabetes mellitus is an important task in modern medicine. In this regard, results of research on the target range of glycemic control in DM2 have a great importance. Optimal mechanism, the rate and degree of reduction of glycated hemoglobin in various categories of patients may be different. Early and reasonable administration of insulin, timely dose titration are crucial to the long-term maintenance of target blood glucose levels in patients with type 2 diabetes mellitus and provide numerous opportunities to achieve the main goals of treatment of DM - maintenance of long-term metabolic control and prevention or delay of vascular complications.</p></abstract><trans-abstract xml:lang="ru"><p>Сахарный диабет типа 2 (СД2) опасен хроническими осложнениями, приводящими к высокой частоте инвалидизации и снижению качества жизни. Предотвращение сосудистых осложнений диабета - важная задача современной медицины. Большое значение в этом плане приобретают результаты исследований, касающихся целевых значений контроля гликемии при СД2. Оптимальный механизм, темп и степень снижения уровня гликированного гемоглобина у разных категорий пациентов могут быть различными. Раннее и обоснованное назначение инсулина, своевременная титрация его дозы являются решающими факторами в длительном поддержании целевых уровней гликемии у больных СД2 и открывают широкие возможности достижения основных целей лечения СД - поддержания долгосрочного метаболического контроля и предотвращения или отсрочки сосудистых осложнений.</p></trans-abstract><kwd-group xml:lang="en"><kwd>type 2 diabetes mellitus</kwd><kwd>vascular complications</kwd><kwd>glycemic control</kwd><kwd>insulin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>сахарный диабет типа 2</kwd><kwd>сосудистые осложнения</kwd><kwd>контроль гликемии</kwd><kwd>инсулинотерапия</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Дедов И.И., Шестакова М.В. Проблемы контроля качества диабетологической службы в России по данным на январь 2007 г. // Сахарный диабет. 2007. № 3. С. 55-57.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ruigomez A, Rodrigues LA. Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol 1998;14(15):439-45.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Shim WS, Kim SK, Kim HJ. Decremental of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol 2006;155(4):615-22.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>O'Rahilly S, John Savill J. Science, medicine, and the future non-insulin dependent diabetes mellitus: the gathering storm. BMJ 1997;314(29):955-67.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>The UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Dluhy RG, McMahon GT. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N Engl J Med 2008;358:2630-33.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Gerstein HC, Miller ME, Byington RP. et al. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group.. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med2008;358:2560-72.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ray KK, Rao S, Seshasai K, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Sheikh-Ali M, Chehade JM. Initiation of insulin therapy in older adults. Geriatrics and aging. 2009;12(3):135-40.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Дедов И.И., Шестакова М.В. Оптимизация и интенсификация инсулинотерапии при сахарном диабете 2 типа (клинические рекомендации) // Сахарный диабет. 2007. Спецвыпуск. С. 9-55.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Robertson C. Physiologic insulin replacement in type 2 diabetes. Diabetes Educator 2006;3:423-32.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>DeWitt DE, Hirch IB. Outpatient insulin therapy in type 1 and 2 diabetes mellitus. JAMA 2003;289(17):2254-64.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Hirsch Irl B Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clinical Diabetes 2005;2(23):78-86.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Turner HE, Matthews DR. The use of fixed-mixture insulins in clinical practice. Eur J Clin Pharmacol 2000;56:19-25.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>White JR Jr, Campbell RK, Hirsch I. Insulin analogues: new agents for improving glycemic control. Postgrad Med 1997;101(2):58-70.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Rizvi AA, Ligthelm RJ. The Use of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: advantages and limitations. Insulin 2007;2:68-79.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Garber AJ, Ligthelm R, Christiansen JS, et al. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007;9(5):630-39.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Garber AJ. Premixed Insulin Analogues for the treatment of Diabetes Mellitus. Drugs 2006;66(1):31-49.</mixed-citation></ref></ref-list></back></article>
